Table 2. Number of participants who completed a heterologous schedule following clinical advise after a severe reaction to the first dose, with no previous symptoms of COVID-19 or confirmed infection who reported local and systemic symptoms after prime and boosting doses of COVID-19 vaccines by vaccination schedule, 29 March−1 June 2021, England.
| Reactions | Prime | Boost | ||||||
|---|---|---|---|---|---|---|---|---|
| ChAd/BNT (n=152) |
BNT/ChAd (n = 36) |
ChAd/BNT (n = 152) |
BNT/ChAd (n =36) |
|||||
| n | % (95%CI) | n | % (95%CI) | n | % (95%CI) | n | %(95%CI) | |
| Systemic | ||||||||
| Fever | 90 | 59.2 (52.6–68.7) | 13 | 36.1 (20.8–53.8) | 16 | 10.8 (6.3–17.0) | 11 | 30.6 (16.3–48.1) |
| Chills | 88 | 57.9 (51.1–67.4) | 13 | 36.1 (20.8–53.8) | 29 | 19.1 (13.5–26.9) | 17 | 47.2 (30.4–64.5) |
| Headache | 105 | 69.1 (61.1–76.3) | 16 | 44.4 (28.0–61.9) | 42 | 27.6 (21.3–36.4) | 19 | 52.8 (35.5–69.6) |
| Unwell | 115 | 75.6 (70.1–84.1) | 21 | 58.3 (40.8–74.5) | 38 | 25 (18.9–33.5) | 17 | 47.2 (30.4–64.5) |
| Tiredness | 108 | 71.1 (65.1–79.9) | 20 | 55.6 (38.1–72.1) | 39 | 25.7 (19.5–34.2) | 20 | 55.6 (38.1–72.1) |
| Joint pain | 86 | 56.6 (49.7–66.2) | 15 | 41.7 (25.5–59.2) | 20 | 13.2 (8.5–20.1) | 14 | 38.9 (23.1–56.5) |
| Nausea | 58 | 38.2 (31.3–47.5) | 10 | 28.0 (14.2–45.2) | 12 | 7.9 (4.3–13.7) | 5 | 13.9 (4.7–29.5) |
| Local | ||||||||
| Pain | 80 | 52.6 (45.7–62.3) | 21 | 58.3 (40.8–74.5) | 46 | 30.3 (23.7–39.2) | 16 | 44.4 (28.0–61.9) |
| Tenderness | 69 | 45.4 (38.4–55.0) | 20 | 55.6 (38.1–72.1) | 43 | 28.3 (21.9–37.1) | 17 | 47.2 (30.4–64.5) |
| Itch | 17 | 11.2 (6.8–17.6) | 5 | 13.9 (4.7–29.5) | 8 | 5.3 (2.4–10.4) | 1 | 2.8 (0.1–14.5) |
| Redness | 32 | 21.1 (83.8–94.2) | 6 | 16.7 (6.4–32.8) | 11 | 7.2 (3.8–12.9) | 6 | 16.7 (6.4–32.8) |
| Total | ||||||||
| Systemic | 133 | 87.5 (52.5–68.7) | 24 | 66.7 (49.0–81.4) | 63 | 41.5 (34.5–50.1) | 25 | 69.4 (51.9–83.7) |
| Local | 90 | 59.2 (90.5–98.1) | 26 | 72.2 (54.8–85.8) | 57 | 37.5 (30.6–46.9) | 19 | 52.8 (35.5–69.6) |
| Overall | 141 | 93.4 (90.5–98.1) | 33 | 91.7 (77.5–98.2) | 73 | 48.0 (41.0–57.7) | 27 | 75.0 (57.8–87.9) |
| Medical attention | 93 | 61.2 (53.0–69.0) | 17 | 47.2 (30.4–64.5) | 10 | 6.6 (3.2-11.8)) | 7 | 19.4 (8.2–36.0) |
BNT: Comirnaty (BNT162b2, BioNTech-Pfizer, Mainz, Germany/New York, United States); ChAd: Vaxrevia (ChAdOx1/nCoV-19, AstraZeneca, Cambridge, United Kingdom).
Please note individuals could report more than one reaction therefore totals do not match the sum of the symptoms.